Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas

Kristin J. Redmond, Christopher L. Wolfgang, Elizabeth A. Sugar, Julia Ahn, Hari Nathan, Daniel Laheru, Barish H. Edil, Michael A. Choti, Timothy M. Pawlik, Ralph H. Hruban, John L. Cameron, Joseph M. Herman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: This study was designed to examine the effect of adjuvant 5-FU-based chemoradiation therapy (CRT) after distal pancreatectomy for adenocarcinoma of the distal pancreas. Methods: All patients underwent curative resection for adenocarcinoma of the distal pancreas between December 1985 and June 2006. Patients who received adjuvant CRT were compared with those who underwent surgery alone. A Kaplan-Meier estimate of the survival curve was used to determine estimates of the median survival and proportion alive at 1 and 2 years; log-rank tests were used to make comparisons between groups. Results: A total of 123 patients underwent distal pancreatectomy; 29 patients were excluded for distant metastases at the time of surgery (n = 12, 10%) or before adjuvant therapy (n = 11, 9%), death within 2 months of surgery (n = 2, 2%), or if CRT treatment status was unknown (n = 4, 3%). Of the remaining 94 patients, 72% received adjuvant 5-FU-based CRT and 28% underwent surgery alone. Overall median survival was 16.2 (95% confidence interval (CI), 13.1-18.9) months. The groups were similar with respect to tumor size, nodal status, and margin status. There was no significant difference in overall survival between patients treated with adjuvant CRT versus surgery alone (p = 0.23). An exploratory subgroup analysis suggested a potential survival benefit of adjuvant CRT in patients with lymph node metastases (16.7 vs. 12.1 months, p < 0.01). Conclusions: Adjuvant CRT did not increase survival compared with surgery alone; however, patients with node-positive disease appear to benefit from adjuvant CRT.

Original languageEnglish (US)
Pages (from-to)3112-3119
Number of pages8
JournalAnnals of Surgical Oncology
Volume17
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Pancreas
Adenocarcinoma
Survival
Therapeutics
Pancreatectomy
Kaplan-Meier Estimate
Fluorouracil
Neoplasm Metastasis
Lymph Nodes
Confidence Intervals

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Redmond, K. J., Wolfgang, C. L., Sugar, E. A., Ahn, J., Nathan, H., Laheru, D., ... Herman, J. M. (2010). Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Annals of Surgical Oncology, 17(12), 3112-3119. https://doi.org/10.1245/s10434-010-1200-3

Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. / Redmond, Kristin J.; Wolfgang, Christopher L.; Sugar, Elizabeth A.; Ahn, Julia; Nathan, Hari; Laheru, Daniel; Edil, Barish H.; Choti, Michael A.; Pawlik, Timothy M.; Hruban, Ralph H.; Cameron, John L.; Herman, Joseph M.

In: Annals of Surgical Oncology, Vol. 17, No. 12, 12.2010, p. 3112-3119.

Research output: Contribution to journalArticle

Redmond, KJ, Wolfgang, CL, Sugar, EA, Ahn, J, Nathan, H, Laheru, D, Edil, BH, Choti, MA, Pawlik, TM, Hruban, RH, Cameron, JL & Herman, JM 2010, 'Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas', Annals of Surgical Oncology, vol. 17, no. 12, pp. 3112-3119. https://doi.org/10.1245/s10434-010-1200-3
Redmond KJ, Wolfgang CL, Sugar EA, Ahn J, Nathan H, Laheru D et al. Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Annals of Surgical Oncology. 2010 Dec;17(12):3112-3119. https://doi.org/10.1245/s10434-010-1200-3
Redmond, Kristin J. ; Wolfgang, Christopher L. ; Sugar, Elizabeth A. ; Ahn, Julia ; Nathan, Hari ; Laheru, Daniel ; Edil, Barish H. ; Choti, Michael A. ; Pawlik, Timothy M. ; Hruban, Ralph H. ; Cameron, John L. ; Herman, Joseph M. / Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. In: Annals of Surgical Oncology. 2010 ; Vol. 17, No. 12. pp. 3112-3119.
@article{fee64052a7a24865a18d9fd7dac33186,
title = "Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas",
abstract = "Background: This study was designed to examine the effect of adjuvant 5-FU-based chemoradiation therapy (CRT) after distal pancreatectomy for adenocarcinoma of the distal pancreas. Methods: All patients underwent curative resection for adenocarcinoma of the distal pancreas between December 1985 and June 2006. Patients who received adjuvant CRT were compared with those who underwent surgery alone. A Kaplan-Meier estimate of the survival curve was used to determine estimates of the median survival and proportion alive at 1 and 2 years; log-rank tests were used to make comparisons between groups. Results: A total of 123 patients underwent distal pancreatectomy; 29 patients were excluded for distant metastases at the time of surgery (n = 12, 10{\%}) or before adjuvant therapy (n = 11, 9{\%}), death within 2 months of surgery (n = 2, 2{\%}), or if CRT treatment status was unknown (n = 4, 3{\%}). Of the remaining 94 patients, 72{\%} received adjuvant 5-FU-based CRT and 28{\%} underwent surgery alone. Overall median survival was 16.2 (95{\%} confidence interval (CI), 13.1-18.9) months. The groups were similar with respect to tumor size, nodal status, and margin status. There was no significant difference in overall survival between patients treated with adjuvant CRT versus surgery alone (p = 0.23). An exploratory subgroup analysis suggested a potential survival benefit of adjuvant CRT in patients with lymph node metastases (16.7 vs. 12.1 months, p < 0.01). Conclusions: Adjuvant CRT did not increase survival compared with surgery alone; however, patients with node-positive disease appear to benefit from adjuvant CRT.",
author = "Redmond, {Kristin J.} and Wolfgang, {Christopher L.} and Sugar, {Elizabeth A.} and Julia Ahn and Hari Nathan and Daniel Laheru and Edil, {Barish H.} and Choti, {Michael A.} and Pawlik, {Timothy M.} and Hruban, {Ralph H.} and Cameron, {John L.} and Herman, {Joseph M.}",
year = "2010",
month = "12",
doi = "10.1245/s10434-010-1200-3",
language = "English (US)",
volume = "17",
pages = "3112--3119",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas

AU - Redmond, Kristin J.

AU - Wolfgang, Christopher L.

AU - Sugar, Elizabeth A.

AU - Ahn, Julia

AU - Nathan, Hari

AU - Laheru, Daniel

AU - Edil, Barish H.

AU - Choti, Michael A.

AU - Pawlik, Timothy M.

AU - Hruban, Ralph H.

AU - Cameron, John L.

AU - Herman, Joseph M.

PY - 2010/12

Y1 - 2010/12

N2 - Background: This study was designed to examine the effect of adjuvant 5-FU-based chemoradiation therapy (CRT) after distal pancreatectomy for adenocarcinoma of the distal pancreas. Methods: All patients underwent curative resection for adenocarcinoma of the distal pancreas between December 1985 and June 2006. Patients who received adjuvant CRT were compared with those who underwent surgery alone. A Kaplan-Meier estimate of the survival curve was used to determine estimates of the median survival and proportion alive at 1 and 2 years; log-rank tests were used to make comparisons between groups. Results: A total of 123 patients underwent distal pancreatectomy; 29 patients were excluded for distant metastases at the time of surgery (n = 12, 10%) or before adjuvant therapy (n = 11, 9%), death within 2 months of surgery (n = 2, 2%), or if CRT treatment status was unknown (n = 4, 3%). Of the remaining 94 patients, 72% received adjuvant 5-FU-based CRT and 28% underwent surgery alone. Overall median survival was 16.2 (95% confidence interval (CI), 13.1-18.9) months. The groups were similar with respect to tumor size, nodal status, and margin status. There was no significant difference in overall survival between patients treated with adjuvant CRT versus surgery alone (p = 0.23). An exploratory subgroup analysis suggested a potential survival benefit of adjuvant CRT in patients with lymph node metastases (16.7 vs. 12.1 months, p < 0.01). Conclusions: Adjuvant CRT did not increase survival compared with surgery alone; however, patients with node-positive disease appear to benefit from adjuvant CRT.

AB - Background: This study was designed to examine the effect of adjuvant 5-FU-based chemoradiation therapy (CRT) after distal pancreatectomy for adenocarcinoma of the distal pancreas. Methods: All patients underwent curative resection for adenocarcinoma of the distal pancreas between December 1985 and June 2006. Patients who received adjuvant CRT were compared with those who underwent surgery alone. A Kaplan-Meier estimate of the survival curve was used to determine estimates of the median survival and proportion alive at 1 and 2 years; log-rank tests were used to make comparisons between groups. Results: A total of 123 patients underwent distal pancreatectomy; 29 patients were excluded for distant metastases at the time of surgery (n = 12, 10%) or before adjuvant therapy (n = 11, 9%), death within 2 months of surgery (n = 2, 2%), or if CRT treatment status was unknown (n = 4, 3%). Of the remaining 94 patients, 72% received adjuvant 5-FU-based CRT and 28% underwent surgery alone. Overall median survival was 16.2 (95% confidence interval (CI), 13.1-18.9) months. The groups were similar with respect to tumor size, nodal status, and margin status. There was no significant difference in overall survival between patients treated with adjuvant CRT versus surgery alone (p = 0.23). An exploratory subgroup analysis suggested a potential survival benefit of adjuvant CRT in patients with lymph node metastases (16.7 vs. 12.1 months, p < 0.01). Conclusions: Adjuvant CRT did not increase survival compared with surgery alone; however, patients with node-positive disease appear to benefit from adjuvant CRT.

UR - http://www.scopus.com/inward/record.url?scp=78650992446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650992446&partnerID=8YFLogxK

U2 - 10.1245/s10434-010-1200-3

DO - 10.1245/s10434-010-1200-3

M3 - Article

VL - 17

SP - 3112

EP - 3119

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 12

ER -